| Michael Landsittel |
mla********@blueprintmedicines.com
|
Lengo Therapeutics |
Chief Financial Officer |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Andy Boral |
abo***@blueprintmedicines.com
|
Lengo Therapeutics |
Executive Vice President, Clinical Development |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Jason Brubaker |
jbr******@blueprintmedicines.com
|
Lengo Therapeutics |
Vice President, Head of Medicinal Chemistry |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Philina Lee |
ple*@blueprintmedicines.com
|
Lengo Therapeutics |
Chief Commercial Officer |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Debbie Durso-Bumpus |
ddu**********@blueprintmedicines.com
|
Lengo Therapeutics |
Chief People Officer |
Biotechnology Research |
United States |
United States |
| Helen Ho |
[email protected]
|
Lengo Therapeutics |
Chief Business Officer |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Tracey McCain |
tmc****@blueprintmedicines.com
|
Lengo Therapeutics |
Executive Vice President and Chief Legal Officer |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Ingrid Andrade |
ian*****@blueprintmedicines.com
|
Lengo Therapeutics |
Manager, Corporate Communications |
Biotechnology Research |
Cambridge, MA, US |
United States |
| Sean Flanagan |
sfl******@blueprintmedicines.com
|
Lengo Therapeutics |
Vice President Sales |
Biotechnology Research |
Boston, MA, US |
United States |
| Shuree Harrison |
sha******@blueprintmedicines.com
|
Lengo Therapeutics |
Vice President, Clinical Operations |
Biotechnology Research |
Cambridge, MA, US |
United States |